Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Week in Review: Fosun Pharma Acquires Majority Stake in China Vaccine Company for $682 Million
Deals and Financings
Shanghai Fosun Pharma (SHA: 600196; HK: 02196) announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company (see story). Fosun paid $174 million to nine Antejin shareholders, and it contributed its own vaccine subsidiary, Dalian Aleph Biomedical at a value of $454 million, for the remainder. Antejin is developing a 13-valent pneumonia vaccine intended for infants, a competitor to Pfizer’s Prevnar 13. In the
SPH SINE, a subsidiary of
Novadip Biosciences of Belgium raised $22 million in a Series B round from global investors including CR-CP Life Science Fund of Hong Kong (see story). Novadip is a clinical stage company developing products to regenerate impaired skeletal tissue. Its proprietary 3M3 platform is a 3-dimensional, extracellular matrix that uses adipose-derived stem cells to deliver growth factors and miRNAs that mimic natural healing. The company's lead candidate is an autologous bone product aimed at diseases that include congenital pseudarthrosis of the tibia (CPT), a rare pediatric disease.
Silenseed, a Tel Aviv RNAi company, raised $7.8 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to start a China JV (see story). Silenseed-China will own the rights to develop, market and sell Silenseed’s RNAi products in
SciNeuro, a Shanghai-Maryland CNS biopharma, formed a multi-program collaboration with
Deals and Financings
Suzhou Alphamab Oncology (HK: 9966) started a China Phase II/III trial of its PD-L1/CTLA-4 bispecific antibody in patients with NSCLC who progressed after an anti-PD-L1 treatment (see story). In the Phase III part of the trial, Alphamab will recruit about 486 patients aimed at OS and PFS as co-primary endpoints. In the trial, KN046 will be combined with lenvatinib and compared to docetaxel. The BLA for the PD-L1 alone has been accepted in
Suzhou Innovent (HK: 01801) and Shenzhen NeoCura will test a combination of Innovent's PD-1, sintilimab, and NeoCura's individual neoantigen mRNA vaccine in patients with solid tumor cancers (see story). NeoCura's NEO_PLIN2101, a mRNA vaccine encoded corresponding neoantigen, is synthesized in vitro and vaccinated into patients to activate tumor-specific T cells. The company believes its patient-based vaccine has better specificity and immunogenicity than other therapies. Innovent will conduct a
Angel Pharma, a Jiaxing-